Patents by Inventor Paul Adriaan Van Der Schaaf

Paul Adriaan Van Der Schaaf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200148644
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: January 13, 2020
    Publication date: May 14, 2020
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Publication number: 20190256469
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: May 1, 2019
    Publication date: August 22, 2019
    Applicant: NISSAN CHEMICAL CORPORATION
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20180346425
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 6, 2018
    Applicant: Nissan Chemical Industries, Ltd.
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20180029987
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: October 5, 2017
    Publication date: February 1, 2018
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20170022163
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Publication number: 20160024010
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: October 1, 2015
    Publication date: January 28, 2016
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Patent number: 9012899
    Abstract: This invention relates to electroluminescent metal complexes of the formula (I) wherein the ring A, represents an optionally substituted aryl group which can optionally contain heteroatoms, the ring B, represents an optionally substituted nitrogen containing aryl group, which can optionally contain further heteroatoms, or the ring A may be taken with the ring B binding to the ring A to form a ring; the group C, represents an acyclic carbene, or a cyclic carbene (ring C), which can optionally contain heteroatoms, the ring D, represents an optionally substituted aryl group which can optionally contain heteroatoms, n1 is an integer of 1 to 3, m1 is an integer of 0, 1 or 2, m2 is an integer 0 or 1, M1 is a metal with an atomic weight of greater than 40, L3 is a monodentate ligand or a bidentate ligand, Y is —C(?O)— or —C(X1)2—, wherein X1 is hydrogen or C1-4alkyl, especially hydrogen and y is 0 or 1, especially 0; a process for their preparation, electronic devices comprising the me
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: April 21, 2015
    Assignee: BASF SE
    Inventors: Roger Pretot, Paul Adriaan Van Der Schaaf, Jemima Schmidt, Beat Schmidhalter, Thomas Schafer, Bernd Lamatsch
  • Publication number: 20140364614
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz BLATTER, Martin SZELAGIEWICZ, Kai-Uwe SCHOENING
  • Patent number: 8853405
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: October 7, 2014
    Assignee: Nissan Chemical Industries Ltd.
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Patent number: 8685541
    Abstract: Disclosed are electroluminescent materials comprising a homopolymer based on recurring structural units of the formula (I) wherein R9, R9? R9?, R11, R13 R14, R11?, R13?, R14? independently are H or an organic substituent, where at least one of R9, R9? R9?, R11, R13 R14, R11?, R13?, R14? comprises a group R10 of the formula —(Sp)x10-[PG?]< wherein Sp is a divalent organic spacer, PG? is a group derived from a polymerizable group, and x10 is 0 or 1, with substituents and spacer as defined in claim 1. Further disclosed are some novel polymers of this class as well as monomers for their preparation. The homopolymers are advantageously used as a host material in devices further comprising a luminescent component, which is usually selected from phosphorescent metal complexes and fluorescent dopants.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: April 1, 2014
    Assignee: BASF SE
    Inventors: Natalia Chebotareva, Roger Pretot, Paul Adriaan Van Der Schaaf, Annemarie Wolleb, Heinz Wolleb
  • Publication number: 20140005402
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Application
    Filed: September 3, 2013
    Publication date: January 2, 2014
    Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.
    Inventors: Paul Adriaan VAN DER SCHAAF, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Patent number: 8557993
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous forms.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: October 15, 2013
    Assignee: Nissan Chemical Industries Ltd.
    Inventors: Paul Adriaan Van der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schoening
  • Patent number: 8492749
    Abstract: This invention relates to electroluminescent metal complexes of the formula (I), wherein the ring A, formula (II), represents an optionally substituted aryl group which can optionally contain heteroatoms, the ring B, formula (III), represents an optionally substituted nitrogen containing aryl group, which can optionally contain further heteroatoms, or the ring A may be taken with the ring B binding to the ring A to form a ring; the group C, formula (IV), represents an acyclic carbene, or a cyclic carbene (ring C), which can optionally contain heteroatoms, the ring D, formula (V), represents an optionally substituted aryl group which can optionally contain heteroatoms, n1 is an integer of 1 to 3, m1 is an integer of 0, 1, or 2, m2 is an integer 0, or 1, M1 is a metal with an atomic weight of greater than 40, L3 is a monodentate ligand, or a bidentate ligand, Y is —C(?O)—, or —C(X1)2-, wherein X1 is hydrogen, or C1-4alkyl, especially hydrogen, and y is 0, or 1, especially 0; a process for their preparation, ele
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: July 23, 2013
    Assignee: BASF SE
    Inventors: Roger Prétôt, Paul Adriaan Van Der Schaaf, Jemima Schmidt, Beat Schmidhalter, Thomas Schäfer, Bernd Lamatsch
  • Publication number: 20120128611
    Abstract: Disclosed is the use of a UV filter combination, comprising (a) a first UV filter selected from benzylidene malonates of formula (1), wherein R1 methyl; ethyl; propyl; or n-butyl; if R1 is methyl, then R is tert.
    Type: Application
    Filed: June 29, 2010
    Publication date: May 24, 2012
    Applicant: BASF SE
    Inventors: Julie Grumelard, Thomas Ehlis, Paul Adriaan Van Der Schaaf, Markus Hansch, Myriam Sohn
  • Patent number: 8177901
    Abstract: The present invention relates to a process for the production of porous inorganic materials or a matrix material containing nanoparticles with high uniformity of thickness and/or high effective surface area and to the materials obtainable by this process. By the above-mentioned process materials with a defined thickness in the region of ±10%, preferably ±5% of the average thickness are available.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: May 15, 2012
    Assignee: BASF SE Ludwigshafen
    Inventors: Patrice Bujard, Andreas Mühlebach, Paul Adriaan Van Der Schaaf
  • Publication number: 20120101126
    Abstract: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
    Type: Application
    Filed: October 25, 2011
    Publication date: April 26, 2012
    Applicant: Nissan Chemical Industries Ltd.
    Inventors: Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, Kai-Uwe Schöning
  • Patent number: 8138303
    Abstract: The present invention relates to novel polymers comprising a repeating unit of the formula (I) and their use in electronic devices. The polymers according to the invention have excellent solubility in organic solvents and excellent film-forming properties. In addition, high charge carrier mobilities and high stability of the emission color can be observed, if the polymers according to the invention are used in organic light emitting diodes (OLEDs).
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: March 20, 2012
    Assignee: BASF SE
    Inventors: Natalia Chebotareva, Roger Prétôt, Paul Adriaan Van der Schaaf, Thomas Schäfer, Beat Schmidhalter, Peter Murer
  • Publication number: 20110159050
    Abstract: Disclosed is a process for modifying the morphology and/or polymorphism of an organic substance, which process comprises treating the solid substance, or a solution or dispersion thereof, with one or more amphiphilic proteins.
    Type: Application
    Filed: June 23, 2009
    Publication date: June 30, 2011
    Applicant: BASF SE
    Inventors: Andreas Hafner, Andreas Buthe, Paul Adriaan Van Der Schaaf, Franz Kaufmann, Gordon Bradley
  • Publication number: 20110114922
    Abstract: This invention relates to electroluminescent metal complexes of the formula (I), wherein the ring A, formula (II), represents an optionally substituted aryl group which can optionally contain heteroatoms, the ring B, formula (III), represents an optionally substituted nitrogen containing aryl group, which can optionally contain further heteroatoms, or the ring A may be taken with the ring B binding to the ring A to form a ring; the group C, formula (IV), represents an acyclic carbene, or a cyclic carbene (ring C), which can optionally contain heteroatoms, the ring D, formula (V), represents an optionally substituted aryl group which can optionally contain heteroatoms, n1 is an integer of 1 to 3, m1 is an integer of 0, 1, or 2, m2 is an integer 0, or 1, M1 is a metal with an atomic weight of greater than 40, L3 is a monodentate ligand, or a bidentate ligand, Y is —C(?O)—, or —C(X1)2-, wherein X1 is hydrogen, or C1-4alkyl, especially hydrogen, and y is 0, or 1, especially 0; a process for their preparation, ele
    Type: Application
    Filed: December 14, 2005
    Publication date: May 19, 2011
    Inventors: Roger Prétôt, Paul Adriaan Van Der Schaaf, Jemima Schmidt, Beat Schmidhalter, Thomas Schäfer, Bernd Lamatsch
  • Patent number: 7932387
    Abstract: Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: April 26, 2011
    Assignee: BASF SE
    Inventors: Fritz Blatter, Paul Adriaan Van Der Schaaf, Martin Szelagiewicz